US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
PMV Pharmaceuticals Inc (PMVP)
PMV Pharmaceuticals Inc (PMVP) ニュース

PMV Pharmaceuticals Inc (PMVP)

1.19

0.03

(2.59%)

終了 6月5日 5:00AM

1.19

0.00

( 0.00% )

プレマーケット: 5:00PM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

PMV Pharmaceuticals Announces Board Chair Transition

PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”;...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy...

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”;...

tw0122

glenn1919

glenn1919 9月前

PMVP................................https://stockcharts.com/h-sc/ui?s=PMVP&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 9月前

PMVP..........................................https://stockcharts.com/h-sc/ui?s=PMVP&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 9月前

pmvp...............................................................................https://stockcharts.com/h-sc/ui?s=PMVP&p=W&b=5&g=0&id=p86431144783

makinezmoney

makinezmoney 9月前

$PMVP: Added some here at $1.40......... only 10k

Lets see what she's got today

Sounds like good news when they say........... PROMISING.

https://finviz.com/news/162242/pmv-pharmaceuticals-announces-promising-rezatapopt-monotherapy-interim-data-from-pynnacle-phase-2-trial-across-multiple-solid-tumors-with-a-tp53-y220c-mutation

GO $PMVP

Monksdream

Monksdream 1年前

Monksdream

Monksdream 2年前

Mt. Blanc

Mt. Blanc 2年前

PMVP had a great move over $3 but then lost control of the jet and sank quickly.

Mt. Blanc

Mt. Blanc 2年前

PMVP into the cup and handle chart setup. On radar to begin climbing the great wall of worry.

mb

Mt. Blanc

Mt. Blanc 3年前

$PMVP trading in the low $2's for now but at some point, this starts to firm up well into 2024+.

mb

Mt. Blanc

Mt. Blanc 3年前

PMVP will be under radar for a while until it catches fire and then will be seen.

mb

crudeoil24

crudeoil24 4年前

2022 American Society of Clinical Oncology (ASCO) Annual Meeting

crudeoil24

crudeoil24 4年前

JUNE 7 > Updated data from ongoing Phase 1/2 PYNNACLE trial to be presented .

crudeoil24

crudeoil24 4年前

PMV Pharma Shares Rise 17%; Company to Present Data on PYNNACLE Phase 1 Trial
6:46 pm ET May 26, 2022 (Dow Jones) Print

By Stephen Nakrosis

Shares of PMV Pharmaceuticals Inc. were trading higher in Thursday's after-hours market, following the company's announcement that it would be presenting data from its lead program, PC14586, at the 2022 American Society of Clinical Oncology meeting next month.

PMV said its abstract describes "preliminary outcomes from 29 patients, including 21 efficacy evaluable, from the ongoing Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation." PMV said the preliminary results "represent the first clinical evidence of targeting a p53 Y220C mutation."

At 6:37 p.m. ET, PMV's shares were trading 17.79% higher at $15.56 a share. Volume at the time topped 2.1 million shares. The company's stock finished the day with a 0.92% gain, closing at $13.21 a share.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

PMVP

crudeoil24

crudeoil24 4年前

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The Company is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.

PMVP

PMV Pharmaceuticals

Amundi US TIPS Gov Infla...

PowerShares S&P SmallCap...

Fox River Resources

UBS SPI Mid ETF

Euronext B Engie 240521 ...

International Parkside P...

AMUNDI SRIH INAV

1.079%19nov46 1.079%19no...

Cacib 5.35% 12mar32 Caci...

BeBop Channel (ID)

Circio Holding ASA

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。